Therapeutics Targeting the Inflammasome After Central Nervous System Injury

Overview

Journal Transl Res

Publisher Elsevier

Specialty Pathology

Date 2015 May 31

PMID 26024799

Citations 60

Authors

Juan Pablo de Rivero Vaccari

W Dalton Dietrich

Robert W Keane

Affiliations

Soon will be listed here.

Abstract

Innate immunity is part of the early response of the body to deal with tissue damage and infections. Because of the early nature of the innate immune inflammatory response, this inflammatory reaction represents an attractive option as a therapeutic target. The inflammasome is a component of the innate immune response involved in the activation of caspase 1 and the processing of pro-interleukin 1β. In this article, we discuss the therapeutic potential of the inflammasome after central nervous system (CNS) injury and stroke, as well as the basic knowledge we have gained so far regarding inflammasome activation in the CNS. In addition, we discuss some of the therapies available or under investigation for the treatment of brain injury, spinal cord injury, and stroke.

Citing Articles

Inflammasome links traumatic brain injury, chronic traumatic encephalopathy, and Alzheimer's disease.

Seplovich G, Bouchi Y, de Rivero Vaccari J, Pareja J, Reisner A, Blackwell L Neural Regen Res. 2024; 20(6):1644-1664.

PMID: 39104096 PMC: 11688549. DOI: 10.4103/NRR.NRR-D-24-00107.

The Interplay of HIV and Long COVID in Sub-Saharan Africa: Mechanisms of Endothelial Dysfunction.

Chikopela T, Mwesigwa N, Masenga S, Kirabo A, Shibao C Curr Cardiol Rep. 2024; 26(9):859-871.

PMID: 38958890 DOI: 10.1007/s11886-024-02087-6.

Increased inflammasome protein expression identified in microglia from postmortem brains with schizophrenia.

Gober R, Dallmeier J, Davis D, Brzostowicki D, de Rivero Vaccari J, Cyr B J Neuropathol Exp Neurol. 2024; 83(11):951-966.

PMID: 38904417 PMC: 11487111. DOI: 10.1093/jnen/nlae066.

Kaempferol Alleviates Hepatic Injury in Nonalcoholic Steatohepatitis (NASH) by Suppressing Neutrophil-Mediated NLRP3-ASC/TMS1-Caspase 3 Signaling.

Yang H, Li D, Gao G Molecules. 2024; 29(11).

PMID: 38893506 PMC: 11173805. DOI: 10.3390/molecules29112630.

Extracellular vesicles mediate inflammasome signaling in the brain and heart of Alzheimer's disease mice.

Cyr B, Cabrera Ranaldi E, Hadad R, Dietrich W, Keane R, de Rivero Vaccari J Front Mol Neurosci. 2024; 17:1369781.

PMID: 38660388 PMC: 11039928. DOI: 10.3389/fnmol.2024.1369781.

References

Varma A, Das A, Wallace 4th G, Barry J, Vertegel A, Ray S . Spinal cord injury: a review of current therapy, future treatments, and basic science frontiers. Neurochem Res. 2013; 38(5):895-905. PMC: 4103794. DOI: 10.1007/s11064-013-0991-6. View

Ma Q, Chen S, Hu Q, Feng H, Zhang J, Tang J . NLRP3 inflammasome contributes to inflammation after intracerebral hemorrhage. Ann Neurol. 2013; 75(2):209-19. PMC: 4386653. DOI: 10.1002/ana.24070. View

de Rivero Vaccari J, Brand 3rd F, Adamczak S, Lee S, Perez-Barcena J, Wang M . Exosome-mediated inflammasome signaling after central nervous system injury. J Neurochem. 2015; 136 Suppl 1:39-48. PMC: 4516699. DOI: 10.1111/jnc.13036. View

Keystone E, Wang M, Layton M, Hollis S, McInnes I . Clinical evaluation of the efficacy of the P2X7 purinergic receptor antagonist AZD9056 on the signs and symptoms of rheumatoid arthritis in patients with active disease despite treatment with methotrexate or sulphasalazine. Ann Rheum Dis. 2012; 71(10):1630-5. DOI: 10.1136/annrheumdis-2011-143578. View

Kigerl K, de Rivero Vaccari J, Dietrich W, Popovich P, Keane R . Pattern recognition receptors and central nervous system repair. Exp Neurol. 2014; 258:5-16. PMC: 4974939. DOI: 10.1016/j.expneurol.2014.01.001. View

Baroja-Mazo A, Martin-Sanchez F, Gomez A, Martinez C, Amores-Iniesta J, Compan V . The NLRP3 inflammasome is released as a particulate danger signal that amplifies the inflammatory response. Nat Immunol. 2014; 15(8):738-48. DOI: 10.1038/ni.2919. View

Beug S, Cheung H, LaCasse E, Korneluk R . Modulation of immune signalling by inhibitors of apoptosis. Trends Immunol. 2012; 33(11):535-45. DOI: 10.1016/j.it.2012.06.004. View

Coleman W, Benzel D, Cahill D, Ducker T, Geisler F, Green B . A critical appraisal of the reporting of the National Acute Spinal Cord Injury Studies (II and III) of methylprednisolone in acute spinal cord injury. J Spinal Disord. 2000; 13(3):185-99. DOI: 10.1097/00002517-200006000-00001. View

North R, Jarvis M . P2X receptors as drug targets. Mol Pharmacol. 2012; 83(4):759-69. PMC: 3608433. DOI: 10.1124/mol.112.083758. View

10.

Adamczak S, Dale G, de Rivero Vaccari J, Ross Bullock M, Dietrich W, Keane R . Inflammasome proteins in cerebrospinal fluid of brain-injured patients as biomarkers of functional outcome: clinical article. J Neurosurg. 2012; 117(6):1119-25. PMC: 3576729. DOI: 10.3171/2012.9.JNS12815. View

11.

Yatsiv I, Morganti-Kossmann M, Perez D, Dinarello C, Novick D, Rubinstein M . Elevated intracranial IL-18 in humans and mice after traumatic brain injury and evidence of neuroprotective effects of IL-18-binding protein after experimental closed head injury. J Cereb Blood Flow Metab. 2002; 22(8):971-8. DOI: 10.1097/00004647-200208000-00008. View

12.

de Rivero Vaccari J, Lotocki G, Alonso O, Bramlett H, Dietrich W, Keane R . Therapeutic neutralization of the NLRP1 inflammasome reduces the innate immune response and improves histopathology after traumatic brain injury. J Cereb Blood Flow Metab. 2009; 29(7):1251-61. PMC: 2846547. DOI: 10.1038/jcbfm.2009.46. View

13.

Vigano E, Mortellaro A . Caspase-11: the driving factor for noncanonical inflammasomes. Eur J Immunol. 2013; 43(9):2240-5. DOI: 10.1002/eji.201343800. View

14.

Davalos A, Alvarez-Sabin J, Castillo J, Diez-Tejedor E, Ferro J, Martinez-Vila E . Citicoline in the treatment of acute ischaemic stroke: an international, randomised, multicentre, placebo-controlled study (ICTUS trial). Lancet. 2012; 380(9839):349-57. DOI: 10.1016/S0140-6736(12)60813-7. View

15.

Adamczak S, de Rivero Vaccari J, Dale G, Brand 3rd F, Nonner D, Ross Bullock M . Pyroptotic neuronal cell death mediated by the AIM2 inflammasome. J Cereb Blood Flow Metab. 2014; 34(4):621-9. PMC: 3982080. DOI: 10.1038/jcbfm.2013.236. View

16.

Stein D . Progesterone in the treatment of acute traumatic brain injury: a clinical perspective and update. Neuroscience. 2011; 191:101-6. DOI: 10.1016/j.neuroscience.2011.04.013. View

17.

Tomura S, de Rivero Vaccari J, Keane R, Bramlett H, Dietrich W . Effects of therapeutic hypothermia on inflammasome signaling after traumatic brain injury. J Cereb Blood Flow Metab. 2012; 32(10):1939-47. PMC: 3463887. DOI: 10.1038/jcbfm.2012.99. View

18.

Madouri F, Guillou N, Fauconnier L, Marchiol T, Rouxel N, Chenuet P . Caspase-1 activation by NLRP3 inflammasome dampens IL-33-dependent house dust mite-induced allergic lung inflammation. J Mol Cell Biol. 2015; 7(4):351-65. DOI: 10.1093/jmcb/mjv012. View

19.

Nirula R, Diaz-Arrastia R, Brasel K, Weigelt J, Waxman K . Safety and efficacy of erythropoietin in traumatic brain injury patients: a pilot randomized trial. Crit Care Res Pract. 2010; 2010. PMC: 2951080. DOI: 10.1155/2010/209848. View

20.

Coll R, Robertson A, Chae J, Higgins S, Munoz-Planillo R, Inserra M . A small-molecule inhibitor of the NLRP3 inflammasome for the treatment of inflammatory diseases. Nat Med. 2015; 21(3):248-55. PMC: 4392179. DOI: 10.1038/nm.3806. View